Morbidity and Mortality

Crude cervical cancer incidence per 100,000 women (2020): 33.1
Age-standardized cervical cancer incidence per 100,000 women (2020): 50.2
Cumulative risk of cervical cancer, ages 0-74 (2020): 5.0%
Cervical cancer deaths (2019): 3,300
Cervical cancer mortality-to-incidence ratio (2020): 0.72
Population-based cancer registry exists (2021): Yes

Primary Prevention

HPV vaccination programme coverage among girls (2020)

Programme coverage: no data
Coverage by age 15: no data

HPV vaccination programme (2020):
HPV included in national vaccination programme: No
Scale of vaccination programme: -
Year of introduction: -
Primary target cohort: -

Related risk factors:
Tobacco use prevalence, women aged 15+ years (2020): 5%
Condom use at last high-risk sex (2011): 37%
HIV incidence per 1000, women aged 15+ years (2020): 7.44

Fewer than 1 in 10 women have been screened for cervical cancer in the last 5 years

Secondary Prevention

National screening programme for cervical cancer exists (2021): Yes
Primary screening test used (2021): VIA
Target age range of programme (2021): 15-54 years
Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): Yes
Clearly defined referral system exists from primary care to secondary and tertiary care (2021): Yes

Number of radiotherapy units per 10,000 cancer patients (2020): <1
Number of brachytherapy units per 10,000 cancer patients (2020): 0

Treatment and Supportive Care

National guidelines on cervical cancer management exist (2021): Yes

Cancer diagnosis and treatment services generally available (2021):
Cancer centre or cancer department at tertiary level: No
Pathology services (laboratories): Yes
Cancer surgery: Yes
Chemotherapy: Yes
Radiotherapy: Yes

Number of medical staff (per 10,000 cancer patients):
Radiation oncologists (2019): 1
Medical physicists (2019): 1
Surgeons (2013): 73
Radiologists (2019): 2
Nuclear medicine physicians (2019): 0

Palliative care for patients with NCDs in the public health system generally available (2021):
In primary health care facilities: No
In community or home-based care: No

WHO Cervical Cancer Elimination Strategy Targets for 2030

90% of girls fully vaccinated with the HPV vaccine by the age of 15
70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
90% of women identified with cervical disease receive treatment

* Programme coverage: % of national target population (among 9-14-year-old girls)
† Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

See Explanatory Notes for indicator descriptions.